Planned enrollment decreased by 4 participants
Before: 20 participants (planned). After: 16 participants (planned).
Study sponsor: Krystal Biotech, Inc. · KRYS
Primary completion is the date data collection ends for the main study measures, not when results are published.
Before: 20 participants (planned). After: 16 participants (planned).
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: To evaluate the safety and tolerability of KB803. Measure: To evaluate the effect of ophthalmic KB803 versus placebo on frequency of corneal. abrasion symptoms.. After: Measure: To evaluate the safety and tolerability of KB803. Measure: To evaluate the effect of ophthalmic KB803 on frequency of corneal abrasion symptoms..
Before: 16 participants (planned). After: 20 participants (planned).
Before: Mar 2026. After: Dec 2026.